Stefan Antonsson

Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.

Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.

Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.

Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.

Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies.